Age-related decrease of miRNA-92a levels in human CD8+ T-cells correlates with a reduction of naïve T lymphocytes

by Ohyashiki, Michiyo, Ohyashiki, Junko H, Hirota, Ayako, Kobayashi, Chiaki, Ohyashiki, Kazuma
Published 2011

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population

by Ohyashiki, Junko H, Yoneta, Masayuki, Hisatomi, Hisashi, Iwabuchi, Tamiko, Umezu, Tomohiro, Ohyashiki, Kazuma
Published 2012

A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells

by Ohyashiki, Junko H, Hamamura, Ryoko, Kobayashi, Chiaki, Zhang, Yu, Ohyashiki, Kazuma
Published 2008

Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safel...

by Ohyashiki, Junko H, Ohtsuki, Kazushige, Mizoguchi, Izuru, Yoshimoto, Takayuki, Katagiri, Seiichiro, Umezu, Tomohiro, Ohyashiki, Kazuma
Published 2014

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib

by Ohyashiki, Kazuma, Umezu, Tomohiro, Katagiri, Seiichiro, Kobayashi, Chiaki, Azuma, Kenko, Tauchi, Tetsuzo, Okabe, Seiichi, Fukuoka, Yutaka, Ohyashiki, Junko H.
Published 2016

Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse

by Yoshimoto, Takayuki, Mizoguchi, Izuru, Katagiri, Seiichiro, Tauchi, Tetsuzo, Furusawa, Jun-ichi, Chiba, Yukino, Mizuguchi, Junichiro, Ohyashiki, Junko H, Ohyashiki, Kazuma
Published 2014